AnchorDx

The company focuses on developing and commercializing products for early cancer screening and diagnosis. It operates in the precision medicine market, specifically targeting the early detection of high-incidence cancers such as those affecting the lungs, digestive system, and urinary system. AnchorDx's business model involves the research, development, production, and sales of these diagnostic products, as well as providing corresponding detection services to a client base that includes over 300 top-tier hospitals in China. The company's revenue generation is linked to the sale of its diagnostic kits and the provision of its testing services. In September 2024, it was announced that Kindstar Globalgene would acquire a 100% equity stake in AnchorDx.

AnchorDx's core technology revolves around ctDNA high-throughput methylation sequencing, which it applies to non-invasive liquid biopsies. The company has two main product lines based on sample type: "a tube of blood" and "a tube of urine". A key product is PulmoSeek™ Plus, designed for the early diagnosis of lung nodules by differentiating between benign and malignant growths. Another significant product is UriFind®, a non-invasive genetic test for diagnosing bladder cancer. The company also developed the AnchorMonarch® DNA Methylation Analysis Software to standardize and interpret methylation data. These products are supported by large-scale prospective clinical trials, such as the "Thunder Project" for lung cancer diagnosis, which was initiated in 2018.

The company has achieved several key milestones, including launching UriFind® in 2019 and receiving recognition for PulmoSeek™ in the Chinese Expert Consensus on Diagnosis of Early Lung Cancer in 2023. Financially, AnchorDx has progressed through multiple funding rounds, securing a $28 million Series B in 2017 and a $40 million Series C in 2021, with backing from notable investors like OrbiMed, WuXi AppTec, and KingMed Diagnostics.